Rheumatology
Conference Coverage
Abatacept reduced rates of progression to RA, phase 2b trial finds
The study was conducted at 28 sites in the United Kingdom and 3 in The Netherlands.
Conference Coverage
Telitacicept shows efficacy, safety in methotrexate-resistant RA
The investigational drug’s ACR 20 response rate was typical for RA biologic treatments, and the trial’s Chinese patient population didn’t include...
Feature
Cold-water swimming for your health? These docs say jump in
“All you need is some water – enough to submerge your entire body in – that’s less than 68 °F (20 °C).”
Conference Coverage
Novel blood test can detect RA
An experimental assay detects epigenetic features within the unique patterns and sizes of cell-free DNA found in blood, but is it better than...
Conference Coverage
Split-dose methotrexate speeds RA response over single dose
Compared with a single dose, more patients in the split-dose group had improved disease activity at 16 weeks, and fewer needed additional DMARDs,...
Conference Coverage
IV secukinumab, alternative to self-injections, reaches primary endpoints in PsA, axSpA
Two phase 3 trials of the recently approved IV formulation of secukinumab showed its efficacy versus placebo in treating psoriatic arthritis and...
From the Journals
Fibromyalgia, CFS more prevalent in patients with IBS
“We as clinicians should integrate in our practice with regular screening for other somatic disorders in the IBS population ...”
Latest News
First referral guide issued for axial spondyloarthritis
The draft recommendations are a “good first step,” but more awareness around axial spondyloarthritis in the nonrheumatology community is also...
Conference Coverage
Study takes fine-grained look at MACE risk with glucocorticoids in RA
The level of risk for MACE rose with the dose, duration, and recency of GC use, and risk increased significantly at prednisone-equivalent doses as...
Conference Coverage
TNF inhibitors may be OK for treating RA-associated interstitial lung disease
Efficacy, safety findings for the use of TNF inhibitors vs. other biologic disease-modifying antirheumatic drugs in treating RA-ILD contrast with...
Conference Coverage
Apremilast beats placebo in early PsA affecting few joints
Phase 4 trial offers insight into efficacy in patients whose mild cases have gotten less research attention.